Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Conversion Therapy for Initially Unresectable Right-Sided HCC
NCT07480382Not yet recruiting
- Sponsor
- Hongwu Nano
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Hongwu Nano. Primary endpoint: Conversion-to-Surgery Rate at 12 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07480382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480382.